Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

I-Mab Biopharma Co., Ltd

http://www.i-mabbiopharma.com/en/

Latest From I-Mab Biopharma Co., Ltd

Summer Chills: US-China Friction Stirs Up Industry Fear, Hope

Recent serious developments and flare-ups between the US and China send chills in investor community, raising grave concerns and increasing uncertainty over cross-border deals and fund flows, amid an ongoing global health crisis.

Policy & Regulation Politics

IPO Update: Biopharma Stands Out Among Gloomy US Market

While COVID-19 closed the window for most initial public offerings late in the first quarter, drug developers continue to launch IPOs, generating an average return of nearly 21% year-to-date.

Financing Trends

Genexine Counting On Hyleukin-7’s Potential As Versatile I-O Booster

Genexine’s recent M&A activity and foreign partnerships underscore its strategy on pipeline innovative therapeutics and biobetters as well as preparations to secure future growth engines, the Korean firm's vice-president tells Scrip in an interview.

South Korea Business Strategies

Finance Watch: Biopharma Stocks See Big Post-IPO Jumps

Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Tasgen Biotech
    • Third Venture Biopharma
UsernamePublicRestriction

Register